SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-15-072604
Filing Date
2015-10-26
Accepted
2015-10-26 08:13:10
Documents
7
Period of Report
2015-10-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a15-21535_38k.htm 8-K 40087
2 EX-5.1 a15-21535_3ex5d1.htm EX-5.1 30479
3 EX-10.1 a15-21535_3ex10d1.htm EX-10.1 145613
4 EX-99.1 a15-21535_3ex99d1.htm EX-99.1 8773
5 GRAPHIC g215353mmi001.gif GRAPHIC 5538
6 GRAPHIC g215353kgi001.gif GRAPHIC 2085
7 GRAPHIC g215353kgi002.jpg GRAPHIC 3722
  Complete submission text file 0001104659-15-072604.txt   242078
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 151174206
SIC: 2834 Pharmaceutical Preparations